Tuberc Respir Dis > Volume 72(2); 2012 > Article
Tuberculosis and Respiratory Diseases 2012;72(2):207-211.
DOI: https://doi.org/10.4046/trd.2012.72.2.207    Published online February 1, 2012.
A Case of Hemolytic Uremic Syndrome in a Lung Cancer Patient Treated with Gemcitabine.
Youn Jung Park, Keun Suk Yang, Hong Soon Jung, Hee Chul Nam, Seung Hye Jung, Boo Gyoung Kim, Ka Young Kim, Jung Ho Kim, Young Ok Kim, Yu Seon Yun
Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea. junpearl19@naver.com
Abstract
Hemolytic uremic syndrome (HUS) is a rare disorder characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS arises from a wide spectrum of conditions, and chemotherapeutic agents have been reported to be associated with HUS, including Mitomycin, Cisplatin, Bleomycin, and Gemcitabine. A 76-year-old man treated with Gemcitabine due to non-small cell lung cancer developed clinical and laboratory findings compatible with HUS. Gemcitabine was ceased and hemodialysis and plasma exchange were utilized and he recovered. A high level of suspicion for HUS is necessary when cancer patients are treated with Gemcitabine, and prompt recognition and treatment are also essential.
Key Words: Hemolytic-Uremic Syndrome, Gemcitabine, Lung Neoplasms


ABOUT
ARTICLE & TOPICS
Article category

Browse all articles >

Topics

Browse all articles >

BROWSE ARTICLES
FOR CONTRIBUTORS
Editorial Office
101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347    Fax: +82-2-572-6683    E-mail: katrdsubmit@lungkorea.org                

Copyright © 2024 by The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Developed in M2PI

Close layer
prev next